Stockreport

ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF DAYBUE), calling it an "ambition" not formal guidance and noting growth assumptions include NUPLAZID expansion and European approval for DAYBUE. Remlifansirin is the n [Read more]